Tõnu Vanakesa

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa et al. · The Lancet Oncology · 2016 · 497 citations · Full text

Medicine, Immunology, Oncology +16

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

Johan Vansteenkiste, M. Zieliński, A. Linder et al. · Journal of Clinical Oncology · 2013 · 314 citations · Full text

Medicine, Immunology, Oncology +16

Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)

Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa et al. · Annals of Oncology · 2014 · 53 citations

Medicine, Immunology, Oncology +14

Antero-superior approaches in the practice of thoracic surgery

Tõnu Vanakesa, Peter Goldstraw · European Journal of Cardio-Thoracic Surgery · 1999 · 39 citations

Medicine, Oncology, Surgery +11